TCI GENE Inc. (TPEX:6879)
Taiwan · Delayed Price · Currency is TWD 37.30
-1.00 (-2.61%)
At close: Feb 11, 2026
TCI GENE Revenue
TCI GENE had revenue of 141.71M TWD in the half year ending June 30, 2025, a decrease of -5.44%. This brings the company's revenue in the last twelve months to 324.73M, down -6.82% year-over-year. In the year 2024, TCI GENE had annual revenue of 347.54M with 4.10% growth.
Revenue (ttm)
324.73M
Revenue Growth
-6.82%
P/S Ratio
3.12
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 347.54M | 13.68M | 4.10% |
| Dec 31, 2023 | 333.86M | -90.17M | -21.26% |
| Dec 31, 2022 | 424.02M | -8.20M | -1.90% |
| Dec 31, 2021 | 432.22M | 239.27M | 124.01% |
| Dec 31, 2020 | 192.95M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 753.30M |
| Meribank Biotech | 486.52M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| BioLASCO Taiwan | 277.12M |
| GeneReach Biotechnology | 215.32M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |
| Holy Stone Healthcare | 47.51M |